Pilot Study of Hypertrophic Cardiomyopathy & Implantable Cardioverter Defibrillator Assessment: (Subcutaneous vs Transvenous)

Inclusion Criteria: * Hypertrophic Cardiomyopathy and a referred for ICD therapy with no pacing requirement. Exclusion Criteria: * Patients with sustained ventricular tachycardia less than 170 bpm * Patients having an indication for pacing therapy. E.g. sick sinus syndrome. * Patients failing appropriate QRS/T-wave sensing with the automated S-ICD ECG automated patient screening provided by Boston Scientific * A minimum of 1 sensing vector passing in supine, standing. * Patients with incessant ventricular tachycardia * Patients who have had a previous ICD implant * Patient who receives cardiac contractility modulation therapy or are likely to receive cardiac contractility modulation therapy * Patients with a serious known concomitant disease with a life expectancy of less than one year * Patients with circumstances that prevent follow-up (no permanent home or address, transient, etc.) * Patients who are unable to give informed consent * Patients who are not suitable for TV-ICD implantation, according to the discretion of the physician, are not screened for enrolment (SVC occlusion).